Egetis Therapeutics AB (publ)

OM:EGTX Stock Report

Market Cap: SEK 1.5b

Egetis Therapeutics Future Growth

Future criteria checks 5/6

Egetis Therapeutics is forecast to grow earnings and revenue by 107.6% and 55% per annum respectively. EPS is expected to grow by 88.9% per annum. Return on equity is forecast to be -3.8% in 3 years.

Key information

107.6%

Earnings growth rate

88.9%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate55.0%
Future return on equity-3.8%
Analyst coverage

Low

Last updated03 Mar 2025

Recent future growth updates

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Dec 07
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Dec 21
We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Jun 07
Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Jan 19
Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Earnings and Revenue Growth Forecasts

OM:EGTX - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027514-54-129-1291
12/31/2026431862272295
12/31/2025285-117-277-2975
12/31/202446-344-228-228N/A
9/30/202468-319-216-216N/A
6/30/202471-319-247-247N/A
3/31/202463-327-254-254N/A
12/31/202358-327-278-278N/A
9/30/202331-319-299-299N/A
6/30/202324-286-249-249N/A
3/31/202322-240-220-220N/A
12/31/202223-194-173-173N/A
9/30/202220-148-137-137N/A
6/30/202221-113-125-125N/A
3/31/202242-114-128-128N/A
12/31/202138-104-130-130N/A
9/30/202140-147-143-143N/A
6/30/202136-153-137-137N/A
3/31/202133-155-133-133N/A
12/31/202041-178-135-135N/A
9/30/202053-127-124-124N/A
6/30/202056-134-134-134N/A
3/31/202039-127-127-127N/A
12/31/201983-61-63-63N/A
9/30/201977-61-54-54N/A
6/30/201977-48-38-38N/A
3/31/201982-46-39-39N/A
12/31/201828-85-81-81N/A
9/30/201831-95N/A-106N/A
6/30/201824-103N/A-97N/A
3/31/201814-91N/A-90N/A
12/31/201714-88N/A-87N/A
9/30/2017N/A-67N/A-51N/A
6/30/20170-48N/A-49N/A
3/31/2017N/A-44N/A-41N/A
12/31/2016N/A-38N/A-36N/A
9/30/2016N/A-36N/A-36N/A
6/30/2016N/A-39N/A-38N/A
3/31/2016N/A-39N/A-44N/A
12/31/2015N/A-44N/A-51N/A
9/30/2015N/A-53N/A-55N/A
6/30/2015N/A-53N/A-52N/A
3/31/2015N/A-54N/A-47N/A
12/31/2014N/A-48N/A-41N/A
9/30/2014N/A-38N/A-34N/A
6/30/2014N/A-31N/A-31N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EGTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.3%).

Earnings vs Market: EGTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EGTX is expected to become profitable in the next 3 years.

Revenue vs Market: EGTX's revenue (55% per year) is forecast to grow faster than the Swedish market (0.9% per year).

High Growth Revenue: EGTX's revenue (55% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EGTX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 15:43
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Patrick LangstromABG Sundal Collier Sponsored
Oscar Haffen LammBryan Garnier & Co